Tata AIG rejected cashless claim for maintenance therapy of MOG-associated myelitis
My mother was diagnosed with MOG-associated myelitis after two weeks' of hospitalization on 8th May. The insurance covered approx 87% of the total hospitalization expenses.
She had to re-admitted today for second dose of rituximab, which the doctor adviced to be administered over a two-day period of in patient treatment.
However, my cashless claim was rejected on the following ground:
Rejection reason:
As per submitted documents member got admitted for management of MOG associated myelitis . However, the
proposed line of treatment is clinically not indicated and Unproven. Hence, we regret to inform you that the
cashless facility has been denied
Clause:
Unproven/Experimental treatment means the treatment
including drug experimental therapy which is
not based on established medical practice in India, is
treatment experimental or unproven..
What are the chances of my reimbursement? And what steps should I undertake next?